» Articles » PMID: 20149229

A Mouse Model for the Sézary Syndrome

Overview
Publisher Biomed Central
Specialty Oncology
Date 2010 Feb 13
PMID 20149229
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Sézary syndrome is an aggressive leukemic form of cutaneous T cell lymphoma and there is no cure of this disease. Until now there is no true animal model for Sézary syndrome, by which new drugs against the disease could be tested.

Methods: Immune deficient CB-17 SCID beige mice were injected subcutaneously with HUT78 cells, a cell line, derived from a Sézary syndrome patient. Developing tumors were analyzed by immunohistochemistry.

Results: Injected HUT78 cells formed tumors at the site of injection. In contrast to the Sézary syndrome in man, no malignant cells were observed in the blood of tumor bearing CB-17 SCID beige mice. The tumors appeared 44-62 days after injection and tumor bearing mice survived further 25 - 62 days until they had to be euthanized according to the guidelines of the Swiss animal protection law, since the tumors had reached the maximal allowed size.

Conclusion: Although the mouse model does not exactly match the human disease, it will be suited for tests of new substances for the treatment of the Sézary syndrome. The formation of an isolated tumor on the skin has the advantage that the effect of a potential drug can be directly monitored without the use of invasive methods.

Citing Articles

"Next top" mouse models advancing CTCL research.

Luo Y, de Gruijl F, Vermeer M, Tensen C Front Cell Dev Biol. 2024; 12:1372881.

PMID: 38665428 PMC: 11044687. DOI: 10.3389/fcell.2024.1372881.


Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.

Warda A, Staniszewski L, Sabir Z, Livingston S, Sausedo M, Reshi S Cells. 2023; 12(21).

PMID: 37947652 PMC: 10647404. DOI: 10.3390/cells12212575.


Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.

Sorger H, Dey S, Vieyra-Garcia P, Poloske D, Teufelberger A, de Araujo E EMBO Mol Med. 2022; 14(12):e15200.

PMID: 36341492 PMC: 9727928. DOI: 10.15252/emmm.202115200.


Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.

Gill R, Gantchev J, Martinez Villarreal A, Ramchatesingh B, Netchiporouk E, Akilov O Cells. 2022; 11(4).

PMID: 35203244 PMC: 8870189. DOI: 10.3390/cells11040593.


Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.

Poglio S, Prochazkova-Carlotti M, Cherrier F, Gros A, Laharanne E, Pham-Ledard A Leukemia. 2020; 35(6):1696-1709.

PMID: 33106625 PMC: 8179845. DOI: 10.1038/s41375-020-01068-2.


References
1.
Dobbeling U, Dummer R, Laine E, Potoczna N, Qin J, Burg G . Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998; 92(1):252-8. View

2.
Qin J, Kamarashev J, Zhang C, Dummer R, Burg G, Dobbeling U . Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol. 2001; 117(3):583-9. DOI: 10.1046/j.0022-202x.2001.01436.x. View

3.
Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F . Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2008; 58(8):1195-206. PMC: 11030985. DOI: 10.1007/s00262-008-0632-0. View

4.
Dalloul A, Laroche L, Bagot M, Mossalayi M, Fourcade C, Thacker D . Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest. 1992; 90(3):1054-60. PMC: 329964. DOI: 10.1172/JCI115920. View

5.
Girardi M, Edelson R . Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology (Williston Park). 2000; 14(7):1061-70; discussion 1070-4, 1076. View